RT Journal Article
SR Electronic
T1 Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
JF Cancer Discovery
JO Cancer Discov
FD American Association for Cancer Research
SP 1514
OP 1527
DO 10.1158/2159-8290.CD-20-0941
VO 10
IS 10
A1 Rivera, Donna R.
A1 Peters, Solange
A1 Panagiotou, Orestis A.
A1 Shah, Dimpy P.
A1 Kuderer, Nicole M.
A1 Hsu, Chih-Yuan
A1 Rubinstein, Samuel M.
A1 Lee, Brendan J.
A1 Choueiri, Toni K.
A1 de Lima Lopes, Gilberto
A1 Grivas, Petros
A1 Painter, Corrie A.
A1 Rini, Brian I.
A1 Thompson, Michael A.
A1 Arcobello, Jonathan
A1 Bakouny, Ziad
A1 Doroshow, Deborah B.
A1 Egan, Pamela C.
A1 Farmakiotis, Dimitrios
A1 Fecher, Leslie A.
A1 Friese, Christopher R.
A1 Galsky, Matthew D.
A1 Goel, Sanjay
A1 Gupta, Shilpa
A1 Halfdanarson, Thorvardur R.
A1 Halmos, Balazs
A1 Hawley, Jessica E.
A1 Khaki, Ali Raza
A1 Lemmon, Christopher A.
A1 Mishra, Sanjay
A1 Olszewski, Adam J.
A1 Pennell, Nathan A.
A1 Puc, Matthew M.
A1 Revankar, Sanjay G.
A1 Schapira, Lidia
A1 Schmidt, Andrew
A1 Schwartz, Gary K.
A1 Shah, Sumit A.
A1 Wu, Julie T.
A1 Xie, Zhuoer
A1 Yeh, Albert C.
A1 Zhu, Huili
A1 Shyr, Yu
A1 Lyman, Gary H.
A1 Warner, Jeremy L.
YR 2020
UL http://cancerdiscovery.aacrjournals.org/content/10/10/1514.abstract
AB Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials.Significance: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically significant 30-day all-cause mortality benefit with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefit. Treatment receipt reflects clinical decision-making and suggests disparities in medication access.This article is highlighted in the In This Issue feature, p. 1426